Irlanti - englanti - HPRA (Health Products Regulatory Authority)

eli lilly nederland b.v. - human insulin (recombinant dna origin) - suspension for injection - 100 international unit(s)/millilitre - insulins and analogues for injection, intermediate- or long-acting combined with fast-acting; insulin (human)

Singapore - englanti - HSA (Health Sciences Authority)

eli lilly (singapore) pte ltd - insulin (human) (isophane) - injection - 100 iu/ml - insulin (human) (isophane) 100 iu/ml

Singapore - englanti - HSA (Health Sciences Authority)

eli lilly (singapore) pte ltd - insulin (human) - injection - 100 iu/ml - insulin (human) 100 iu/ml

Armenia - englanti - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

lilly france s.a.s. - insulin human isophane (recombinant dna) - suspension for injection - 100iu/ml

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

eli lilly and company limited - human insulin (recombinant dna origin) - suspension for injection - 100 iu/ml - insulin (human) - humulin i - for the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

eli lilly and company limited - human insulin (recombinant dna origin) - suspension for injection - 100 iu/ml - insulin (human) - humulin - for the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis

Australia - englanti - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - insulin lispro, quantity: 100 iu/ml - injection, suspension - excipient ingredients: sodium hydroxide; water for injections; metacresol; protamine sulfate; dibasic sodium phosphate heptahydrate; phenol; glycerol; zinc oxide; hydrochloric acid - indications: for the treatment of patients with type i (iddm) and type ii (niddm) diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - insulin lispro, quantity: 100 iu/ml - injection, suspension - excipient ingredients: hydrochloric acid; glycerol; phenol; water for injections; dibasic sodium phosphate heptahydrate; metacresol; zinc oxide; sodium hydroxide; protamine sulfate - indications: for the treatment of patients with type i (iddm) and type ii (niddm) diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. for the treatment of patients with type i (iddm) and type ii (niddm) diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - insulin lispro, quantity: 100 iu/ml - injection, suspension - excipient ingredients: protamine sulfate; phenol; hydrochloric acid; glycerol; metacresol; sodium hydroxide; zinc oxide; water for injections; dibasic sodium phosphate heptahydrate - for the treatment of patients with type i (iddm) and type ii (niddm) diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - insulin lispro, quantity: 100 iu/ml - injection, suspension - excipient ingredients: zinc oxide; sodium hydroxide; hydrochloric acid; dibasic sodium phosphate heptahydrate; protamine sulfate; phenol; glycerol; water for injections; metacresol - for the treatment of patients with type i (iddm) and type ii (niddm) diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.